13.06
-0.02(-0.15%)
Currency In USD
| Previous Close | 13.08 |
| Open | 13.25 |
| Day High | 13.27 |
| Day Low | 12.88 |
| 52-Week High | 37 |
| 52-Week Low | 9.81 |
| Volume | 24,801 |
| Average Volume | 106,443 |
| Market Cap | 181.44M |
| PE | 0 |
| EPS | 0 |
| Moving Average 50 Days | 12.46 |
| Moving Average 200 Days | 17.99 |
| Change | -0.02 |
If you invested $1000 in Crescent Biopharma, Inc. (CBIO) 10 years ago, it would be worth $95,127.1 as of November 24, 2025 at a share price of $13.06. Whereas If you bought $1000 worth of Crescent Biopharma, Inc. (CBIO) shares 5 years ago, it would be worth $53,636.7 as of November 24, 2025 at a share price of $13.06.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Crescent Biopharma Announces Grants of Inducement Awards
GlobeNewswire Inc.
Nov 17, 2025 9:15 PM GMT
WALTHAM, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the
Crescent Biopharma to Present at November Investor Conferences
GlobeNewswire Inc.
Nov 05, 2025 12:30 PM GMT
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that man
Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
GlobeNewswire Inc.
Nov 04, 2025 2:05 PM GMT
CR-001 Demonstrated Cooperative Pharmacology and Robust Anti-Tumor Activity IND Submission for CR-001 On Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors WALTHAM, Mass., Nov. 04, 2025 (GLO